Dissecting the hemagglutinin head and stalk-specific IgG antibody response in healthcare workers following pandemic H1N1 vaccination

npj Vaccines

Volumn 1, Issue , 2016, Pages

  Tete, Sarah M ^a,b   Krammer, Florian ^c   Lartey, Sarah ^a,b   Bredholt, Geir ^a   Wood, John ^d   Skrede, Steinar ^b   Cox, Rebecca J ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85031295274     PISSN: None     EISSN: 20590105     Source Type: Journal    
DOI: 10.1038/npjvaccines.2016.1     Document Type: Article

References (35)

1. Poland, G. A., Tosh, P. &Jacobson, R. M. Requiring influenza vaccination for health care workers: seven truths we must accept. Vaccine 23, 2251-2255 (2005).
2. Lemaitre, M. et al. Effect of influenza vaccination of nursing home staff on mortality of residents: a cluster-randomized trial. J. Am. Geriatr. Soc. 57, 1580-1586 (2009).
3. Roman, F. et al. Effect on cellular and humoral immune responses of the AS03 adjuvant system in an A/H1N1/2009 influenza virus vaccine administered to adults during two randomized controlled trials. Clin. Vaccine Immunol. 18, 835 (2011).
4. Nicholson, K. G. et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 357, 1937-1943 (2001).
5. Clark, T. W. et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N. Engl. J. Med. 361, 2424 (2009).
6. Zhou, Y. et al. Seroprevalence of pandemic H1N1 antibody among health care workers in Hong Kong following receipt of monovalent 2009 H1N1 influenza vaccine. PLoS ONE 6, e27169 (2011).
7. Madhun, A. S. et al. An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers. Vaccine 29, 266-273 (2010).
8. Greenberg, M. E. et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N. Engl. J. Med. 361, 2405-2413 (2009).
9. Centers for Disease Control and Prevention. Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb. Mortal. Wkly. Rep. 58, 521-524 (2009).
10. Hancock, K. et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N. Engl. J. Med. 361, 1945-1952 (2009).
11. Lazarowitz, S. G. &Choppin, P. W. Enhancement of the infectivity of influenza A and B viruses by proteolytic cleavage of the hemagglutinin polypeptide. Virology 68, 440-454 (1975).
12. Krammer, F. &Palese, P. Universal influenza virus vaccines: need for clinical trials. Nat. Immunol. 15, 3-5 (2014).
13. Wrammert, J. et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J. Exp. Med. 208181 (2011).
14. Pica, N. et al. Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses. Proc. Natl Acad. Sci. USA 109, 2573-2578 (2012).
15. Palese, P. &Wang, T. T. Why do influenza virus subtypes die out? A hypothesis. Mbio 2 (2011).
16. Veguilla, V. et al. Sensitivity and specificity of serologic assays for detection of human infection with 2009 pandemic H1N1 virus in U.S. populations. J. Clin. Microbiol. 49, 2210-2215 (2011).
17. Jegaskanda, S. et al. Age-associated cross-reactive antibody-dependent cellular cytotoxicity toward 2009 pandemic influenza A virus subtype H1N1. J. Infect. Dis. 208, 1051-1061 (2013).
18. Li, Y. et al. Immune history shapes specificity of pandemic H1N1 influenza antibody responses. J. Exp. Med. 210, 1493-1500 (2013).
19. Fonville, J. M. et al. Antibody landscapes after influenza virus infection or vaccination. Science 346, 996-1000 (2014).
20. He, X. S. et al. Heterovariant cross-reactive B-cell responses induced by the 2009 pandemic influenza virus A subtype H1N1 vaccine. J. Infect. Dis. 207, 288-296 (2013).
21. Corti, D. et al. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J. Clin. Invest. 120, 1663 (2010).
22. Sangster, M. Y. et al. B cell response and hemagglutinin stalk-reactive antibody production in different age cohorts following 2009 H1N1 influenza virus vaccination. Clin. Vaccine Immunol. 20, 867-876 (2013).
23. Ellebedy, A. H. et al. Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans. Proc. Natl Acad. Sci. USA 111, 13133-13138 (2014).
24. Li, G. M. et al. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc. Natl Acad. Sci. USA 109, 9047-9052 (2012).
25. Khurana, S., Frasca, D., Blomberg, B. &Golding, H. AID activity in B cells strongly correlates with polyclonal antibody affinity maturation in-vivo following pandemic 2009-H1N1 vaccination in humans. Plos Pathog. 8, e1002920 (2012).
26. Wrammert, J. et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453, 667 (2008).
27. Li, G. M. et al. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc. Natl Acad. Sci. USA 109, 9047-9052 (2012).
28. DiLillo, D. J., Tan, G. S., Palese, P. &Ravetch, J. V. Broadly neutralizing hemagglutinin stalk-specific antibodies require Fcgamma R interactions for protection against influenza virus in vivo. Nat. Med. 20, 143-151 (2014).
29. Corti, D. et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333, 850-856 (2011).
30. Tan, G. S. et al. A pan-H1 anti-hemagglutinin monoclonal antibody with potent broad-spectrum efficacy in vivo. J. Virol. 86, 6179-6188 (2012).
31. Jegaskanda, S. et al. Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity in intravenous immunoglobulin as a potential therapeutic against emerging influenza viruses. J. Infect. Dis. 210, 1811-1822 (2014).
32. Cox, R. J. et al. An early humoral immune response in peripheral blood following parenteral inactivated influenza vaccination. Vaccine 12, 993 (1994).
33. Krammer, F., Pica, N., Hai, R., Margine, I. &Palese, P. Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J. Virol. 87, 6542-6550 (2013).
34. Pedersen, G. K. et al. Serum IgG titres, but not avidity, correlates with neutralizing antibody response after H5N1 vaccination. Vaccine 32, 4550-4557 (2014).
35. Jegaskanda, S. et al. Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies. J. Immunol. 190, 1837 (2013).